On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Shares of AbbVie Inc. ABBV shed 2.74% to $164.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.32% to 5,870.62 and Dow ...

AbbVie Inc. (ABBV) is a global biopharmaceutical company, founded in 2013 as a spinoff from Abbott Laboratories, focusing on discovering and delivering innovative medicines and solutions for complex ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

As of 2024-11-12, AbbVie Inc's intrinsic value as calculated by the Discounted Earnings model is $295.71. It's currently trading at a price of $174.43. Therefore, the margin of safety based on the ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...